Fosun Pharma (02196.HK): The drug registration application for Compound Polyethylene Glycol (3350) Electrolyte Powder has been approved by the National Medical Products Administration.

Fosun Pharma (02196.HK) announced that its subsidiary, Suzhou Er Ye Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Compound Polyethylene Glycol (3350) Electrolyte Powder (hereinafter referred to as "the drug"). The approved indications are: (1) for the treatment of chronic constipation in children aged 1 to 11 years; (2) for the treatment of fecal impaction in children aged 5 to 11 years, namely stubborn constipation accompanied by the accumulation of fecal matter in the rectum and/or colon.